CN106687474A - 新型胰淀素和降钙素受体激动剂 - Google Patents

新型胰淀素和降钙素受体激动剂 Download PDF

Info

Publication number
CN106687474A
CN106687474A CN201580046850.8A CN201580046850A CN106687474A CN 106687474 A CN106687474 A CN 106687474A CN 201580046850 A CN201580046850 A CN 201580046850A CN 106687474 A CN106687474 A CN 106687474A
Authority
CN
China
Prior art keywords
mimylin
peptide
preceding aspects
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580046850.8A
Other languages
English (en)
Chinese (zh)
Inventor
T.克鲁塞
L.舍夫弗
K.达尔
C.波森
K.劳恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN106687474A publication Critical patent/CN106687474A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201580046850.8A 2014-09-04 2015-09-02 新型胰淀素和降钙素受体激动剂 Pending CN106687474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14183551 2014-09-04
EP14183551.2 2014-09-04
PCT/EP2015/069996 WO2016034604A1 (en) 2014-09-04 2015-09-02 Novel amylin and calcitonin receptor agonist

Publications (1)

Publication Number Publication Date
CN106687474A true CN106687474A (zh) 2017-05-17

Family

ID=51483301

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580046850.8A Pending CN106687474A (zh) 2014-09-04 2015-09-02 新型胰淀素和降钙素受体激动剂

Country Status (8)

Country Link
US (2) US9593149B2 (enExample)
EP (1) EP3189071B1 (enExample)
JP (3) JP6728141B2 (enExample)
CN (1) CN106687474A (enExample)
AR (1) AR101742A1 (enExample)
ES (1) ES2887370T3 (enExample)
TW (1) TW201625671A (enExample)
WO (1) WO2016034604A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109248323A (zh) * 2017-07-14 2019-01-22 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
US11274158B2 (en) 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
KR20210091705A (ko) 2018-10-11 2021-07-22 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
TW202440619A (zh) * 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂
KR20250057847A (ko) 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025240893A1 (en) 2024-05-17 2025-11-20 Eli Lilly And Company 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622386A (en) * 1985-03-28 1986-11-11 Armour Pharmaceutical Company [1,7-di-alanine]calcitonin
WO1996040220A1 (en) * 1995-06-07 1996-12-19 Amylin Pharmaceuticals, Inc. Treatment of type ii diabetes mellitus with amylin agonists
CN102076353A (zh) * 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
CN103826655A (zh) * 2011-05-25 2014-05-28 安米林药品有限责任公司 胰岛淀粉样多肽及其衍生物和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4659804A (en) 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
EP0297159A1 (en) * 1987-07-01 1989-01-04 Armour Pharmaceutical Company [N-Acyl, 1,7-Di-Aline] calcitonins, method for their preparation, pharmaceutical compositions and use
AU629552B2 (en) 1988-06-16 1992-10-08 Teijin Limited S-sulfonated calcitonin derivatives
CN1064051C (zh) 1997-04-30 2001-04-04 中国人民解放军军事医学科学院毒物药物研究所 不含二硫键的鲑鱼和鳗鱼降钙素类似物及其制备方法
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1912666A2 (en) 2005-07-22 2008-04-23 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
AU2010206614B2 (en) 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
CN102369018B (zh) 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗
PT2621519T (pt) * 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
MX341324B (es) * 2011-06-10 2016-08-16 Novo Nordisk As Polipeptidos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622386A (en) * 1985-03-28 1986-11-11 Armour Pharmaceutical Company [1,7-di-alanine]calcitonin
WO1996040220A1 (en) * 1995-06-07 1996-12-19 Amylin Pharmaceuticals, Inc. Treatment of type ii diabetes mellitus with amylin agonists
CN102076353A (zh) * 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
CN103826655A (zh) * 2011-05-25 2014-05-28 安米林药品有限责任公司 胰岛淀粉样多肽及其衍生物和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H.E. LEBOVITZ: "New treatments of diabetes: The β-amylin agonists", 《ANNALES D ENDOCRINOLOGIE》 *
严国文等: "抗糖尿病肽类药物研究进展", 《药物生物技术》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109248323A (zh) * 2017-07-14 2019-01-22 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法

Also Published As

Publication number Publication date
US10174082B2 (en) 2019-01-08
WO2016034604A1 (en) 2016-03-10
EP3189071B1 (en) 2021-07-28
US9593149B2 (en) 2017-03-14
JP2022130522A (ja) 2022-09-06
US20170145059A1 (en) 2017-05-25
JP7095027B2 (ja) 2022-07-04
TW201625671A (zh) 2016-07-16
AR101742A1 (es) 2017-01-11
JP2017530108A (ja) 2017-10-12
EP3189071A1 (en) 2017-07-12
JP6728141B2 (ja) 2020-07-22
JP2020169197A (ja) 2020-10-15
US20160272683A1 (en) 2016-09-22
ES2887370T3 (es) 2021-12-22

Similar Documents

Publication Publication Date Title
JP7095027B2 (ja) 新規のアミリン及びカルシトニン受容体アゴニスト
TWI810606B (zh) Gip/glp1共促效劑化合物
CN103649115B (zh) 多肽
TWI694082B (zh) 選擇性ｐｙｙ化合物及其用途
CN102918055B (zh) 新的胰高血糖素类似物
EP3068421B1 (en) Selective pyy compounds and uses thereof
TWI795698B (zh) 腸促胰島素(incretin)類似物及其用途
CN102197049B (zh) 胰岛淀粉样多肽衍生物
CN102933598A (zh) 新型胰高血糖素类似物
EP3204408B1 (en) Stable glp-1 based glp-1/glucagon receptor co-agonists
JP2013505221A (ja) 長時間作用性ｙ２受容体アゴニスト
CN106536547A (zh) 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
CN104395338A (zh) 人胰岛淀粉样多肽类似物
WO2021110845A1 (en) Optimized gip peptide analogues

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination